BFA
GNMX

BlackRock Fund Advisors’s Aevi Genomic Medicine Inc GNMX Stock Holding History

BlackRock Fund Advisors’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$4.59M Buy
886,435
+141,641
+19% +$745K ﹤0.01% 2970
2016
Q3 		$4.15M Buy
744,794
+111,981
+18% +$638K ﹤0.01% 2928
2016
Q2 		$3.51M Buy
632,813
+68,454
+12% +$359K ﹤0.01% 3008
2016
Q1 		$2.48M Sell
564,359
-31,988
-5% -$132K ﹤0.01% 3013
2015
Q4 		$3.59M Buy
596,347
+157,767
+36% +$1.07M ﹤0.01% 2993
2015
Q3 		$3.43M Sell
438,580
-5,160
-1% -$40K ﹤0.01% 2973
2015
Q2 		$2.72M Buy
443,740
+400,900
+936% +$3.11M ﹤0.01% 3117
2015
Q1 		$345K Sell
42,840
-2,912
-6% -$22K ﹤0.01% 3342
2014
Q4 		$232K Buy
45,752
+3,276
+8% +$16.2K ﹤0.01% 3446
2014
Q3 		$220K Sell
42,476
-3,094
-7% -$20K ﹤0.01% 3436
2014
Q2 		$354K Buy
45,570
+1,304
+3% +$9.21K ﹤0.01% 3287
2014
Q1 		$309K Buy
44,266
+9,455
+27% +$73.8K ﹤0.01% 3348
2013
Q4 		$209K Buy
34,811
+7,178
+26% +$46.9K ﹤0.01% 3434
2013
Q3 		$216K Buy
27,633
+2,178
+9% +$10.1K ﹤0.01% 3360
2013
Q2 		$97K Buy
+25,455
New +$104K ﹤0.01% 3532

Other funds holding GNMX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock Fund Advisors's GNMX Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Aevi Genomic Medicine Inc (GNMX) stake by 19% in Q4 2016, buying an estimated $745K and bringing the position to 886,435 shares worth $4.59M. The position accounts for ﹤0.01% of the portfolio, ranked #2970.

BlackRock Fund Advisors first reported a position in GNMX in Q2 2013 and has held it in 15 quarters since. 76 funds tracked by Wall St. Rank hold GNMX as of Q4 2016.

  • BlackRock Fund Advisors held 886,435 shares of Aevi Genomic Medicine Inc worth $4.59M as of Q4 2016.
  • BlackRock Fund Advisors bought 141,641 Aevi Genomic Medicine Inc shares in Q4 2016, an estimated $745K.
  • Aevi Genomic Medicine Inc made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #2970 holding.
  • BlackRock Fund Advisors first reported a position in Aevi Genomic Medicine Inc in Q2 2013 and has held it in 15 quarters since.
  • 76 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.